KCNN4 and ischemic stroke: Here, we present evidence that KCa3.1 represents a valid pharmacological target for modulation of phenotype during astrogliosis caused by ischemic stroke, in both oxygen–glucose deprivation (OGD)-treated astrocytes and in the brains of mice subjected to permanent middle cerebral artery occlusion (pMCAO).